×

Prescriber adoption of newly approved selective COX-2 inhibitors.

  • Author

    Layton D Shakir SA Souverein PC Heerdink ER Egberts AG

    Layton D Shakir SA Souverein PC Heerdink ER Egberts AG

  • Cite

    Pharmacoepidemiol Drug Safety. 2008 Dec;17(12):1168-74

Adverse drug reactions: Neuropsychiatric drug reactions associated with varenicline (Champix).

  • Author

    Layton D and Cox A.

    Layton D Cox A.

  • Cite

    The Pharmaceutical Journal. June 2008

Developing tools for the safety specification in risk management plans: lessons learned from a pilot project.

  • Author

    Shakir S Cooper AJ Lettis S Chapman CL Evans SJ Waller PC Payvandi N Murray AB.

    Shakir S Cooper AJ Lettis S Chapman CL Evans SJ Waller PC Payvandi N Murray AB.

  • Cite

    Pharmacoepidemiol Drug Saf. 2008 May;17(5):445-54

Prescription Event Monitoring in the United Kingdom

  • Author

    Shakir SAW

    Shakir SAW

  • Cite

    Pharmacoepidemiology and Therapeutic Risk Management. April 2008

European commission consultation on pharmacovigilance

  • Author

    Shakir S Moore N Waller P Beard K Egberts T Evans S Hallas J Hasford J Laporte JR Sturkenboom M.

    Shakir S Moore N Waller P Beard K Egberts T Evans S Hallas J Hasford J Laporte JR Sturkenboom M.

  • Cite

    Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):108-9

Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.

  • Author

    Shakir SA. Kasliwal R Wilton LV

    Shakir SA Kasliwal R Wilton LV

  • Cite

    Drug Safety. 2008;31(10):839-50

Safety profile of esomeprazole : results of a prescription-event monitoring study of 11 595 patients in England.

  • Author

    Davies M Shakir SA. Wilton LV

    Davies M Shakir SA Wilton LV

  • Cite

    Drug Safety. 2008;31(4):313-23

Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.

  • Author

    Layton D Shakir SA Souverein PC Heerdink ER Egberts AC.

    Layton D Shakir SA Souverein PC Heerdink ER Egberts AC.

  • Cite

    Drug Saf. 2008;31(2):143-58

Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.

  • Author

    Layton D Shakir SA Wilton LV Twaites B

    Layton D Shakir SA Wilton LV Twaites B

  • Cite

    Acta Diabetol. 2007 Dec;44(4):233-9

The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.

  • Author

    Shakir SA Perrio MJ Wilton LV

    Shakir SA Perrio MJ Wilton LV

  • Cite

    Obesity. 2007 Nov;15(11):2712-22

A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring.

  • Author

    Shakir SA. Perrio MJ Wilton LV

    Shakir SA Perrio MJ Wilton LV

  • Cite

    Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):969-78

The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.

  • Author

    Shakir SA. Wilton LV Twaites BR

    Shakir SA Wilton LV Twaites BR

  • Cite

    J Psychopharmacol. 2007 Jun;21(4):392-9

An analysis of the exclusion criteria used in observational pharmacoepidemiological studies

  • Author

    Shakir SA Perrio M Waller PC

    Shakir SA Perrio M Waller PC

  • Cite

    Pharmacoepidemiol Drug Saf. 2007 Mar;16(3)

An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease.

  • Author

    Hazell L Shakir SA. Wilton LV Boshier A Harris S

    Hazell L Shakir SA Wilton LV Boshier A Harris S

  • Cite

    BJU Int. 2007 Feb;99(2):387-93

Thoughts on signal detection in pharmacovigilance

  • Author

    Shakir SA

    Shakir SA

  • Cite

    Drug Saf. 2007;30(7):603-6

A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.

  • Author

    Shakir SA. Perrio MJ Wilton LV

    Shakir SA Perrio MJ Wilton LV

  • Cite

    Drug Safety. 2007;30(8):681-95.

Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.

  • Author

    Shakir SA. Wilton LV Twaites BR

    Shakir SA Wilton LV Twaites BR

  • Cite

    Drug Saf. 2007;30(5):419-29

Safety profile of rosuvastatin : results of a prescription-event monitoring study of 11 680 patients

  • Author

    Shakir SA Cornelius V Kasliwal R Wilton LV urich-Barrera B

    Shakir SA Cornelius V Kasliwal R Wilton LV urich-Barrera B

  • Cite

    Drug Saf. 2007;30(2):157-70

Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance

  • Author

    Shakir SA. Perrio M Voss S

    Shakir SA Perrio M Voss S

  • Cite

    Drug Saf. 2007;30(4):333-46.

Safety profile of orlistat: results of a prescription-event monitoring study

  • Author

    Shakir SA Wilton LV Acharya NV

    Shakir SA Wilton LV Acharya NV

  • Cite

    Int J Obes (Lond). 2006 Nov;30(11):1645-52

Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes

  • Author

    Shakir S Wilton L Djulus J Koren G Einarson TR av-Citrin O Kennedy D Voyer LS De SM Einarson A

    Shakir S Wilton L Djulus J Koren G Einarson TR av-Citrin O Kennedy D Voyer LS De SM Einarson A

  • Cite

    J Clin Psychiatry. 2006 Aug;67(8):1280-4

Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction

  • Author

    Shakir SA Wilton LV Boshier A Maclennan KM

    Shakir SA Wilton LV Boshier A Maclennan KM

  • Cite

    BJU Int. 2006 Jul;98(1):125-31

Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study

  • Author

    Shakir S Marshall V Wilton L

    Shakir S Marshall V Wilton L

  • Cite

    Acta Diabetol. 2006 May;43(1):6-13

Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England

  • Author

    Layton D Marshall V Shakir SA Boshier A Friedmann P

    Layton D Marshall V Shakir SA Boshier A Friedmann P

  • Cite

    Drug Saf. 2006;29(8):687-96

An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets

  • Author

    Shakir SA Clarke A Deeks JJ

    Shakir SA Clarke A Deeks JJ

  • Cite

    Drug Saf. 2006;29(2):175-81.